FMR LLC Reports 14.3% Stake in Kymera Therapeutics

Kymera Therapeutics ownership update: institutional investor FMR LLC reports beneficial ownership of 11,681,450.45 shares of Common Stock, representing 14.3% of the class.

Rhea-AI Filing Summary

Kymera Therapeutics ownership update: institutional investor FMR LLC reports beneficial ownership of 11,681,450.45 shares of Common Stock, representing 14.3% of the class. The filing lists sole voting power of 11,666,707 and sole dispositive power of 11,681,450.45, with an exhibit referencing a 13d-1(k) agreement.

Insights

Institutional Ownership Analyst

FMR LLC reports a 14.3% stake in KYMERA, disclosed via Schedule 13G/A amendment.

FMR LLC's Schedule 13G/A (Amendment No. 4) shows 11,681,450.45 shares beneficially owned and matching sole dispositive power. The cover lists sole voting power 11,666,707, indicating consolidated control of voting and disposition rights.

The amendment references an attached 13d-1(k) agreement (Exhibit 99) and a power of attorney incorporated by reference. This is a disclosure of large passive/beneficial ownership rather than an operational change; cash-flow treatment and trading intent are not stated in the excerpt.

Key Figures

Beneficial ownership: 11,681,450.45 shares Percent of class: 14.3% Sole voting power: 11,666,707 +3 more

6 metrics

Beneficial ownership 11,681,450.45 shares Amount beneficially owned reported on the Schedule 13G/A

Percent of class 14.3% Percent of common stock represented by the reported shares

Sole voting power 11,666,707 Sole power to vote reported on the cover information

Sole dispositive power 11,681,450.45 Sole power to dispose reported on the cover information

Filing type Schedule 13G/A (Amendment No. 4) Form type disclosed at top of excerpt

Exhibit referenced Exhibit 99 (13d-1(k) agreement) Exhibit information cited in the amendment

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power, 13d-1(k) agreement

4 terms

Schedule 13G/A regulatory

"Amendment No. 4 ) KYMERA THERAPEUTICS INC COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 11681450.45"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power financial

"7 | Sole Dispositive Power 11,681,450.45"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

13d-1(k) agreement regulatory

"Exhibit 99 for 13d-1(k) (1) agreement."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in KYMR?

FMR LLC reports beneficial ownership of 11,681,450.45 shares, equal to 14.3% of Kymera Therapeutics' common stock as disclosed in the amendment.

What voting and dispositive powers does FMR LLC hold for KYMR?

The filing lists sole voting power of 11,666,707 shares and sole dispositive power of 11,681,450.45 shares for FMR LLC in Kymera Therapeutics.

Does the Schedule 13G/A indicate trading intent by FMR LLC?

The amendment reports beneficial ownership and power figures but does not state trading intent or plans; the excerpt does not disclose whether holdings are passive or active.

What is the significance of the referenced Exhibit 99?

Exhibit 99 is cited as the 13d-1(k) agreement attached to the amendment; the excerpt notes its existence but does not include the agreement's terms or effects.

Who signed the amendment for FMR LLC?

The amendment is signed by Richard Bourgelas as duly authorized under a Power of Attorney dated April 13, 2026, on behalf of FMR LLC and Abigail P. Johnson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 11:23 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

KYMERA THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

501575104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,666,707.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,681,450.45
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,681,450.45

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,681,450.45
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,681,450.45

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KYMERA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 500 NORTH BEACON STREET, 4TH FLOOR,WATERTOWN,MA,USA,02472
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 501575104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11681450.45
(b)	Percent of class: 14.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 11681450.45
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KYMERA THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of KYMERA THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.